PerkinElmer unveils CE-marked infectious disease immunoassays on EUROIMMUN random access instrument

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the first two CE-marked chemiluminescence immunoassays (ChLIA) for the detection of anti-Borrelia (Lyme disease) and anti-EBV/EBNA (Epstein-Barr Virus) antibodies on its EUROIMMUN RA Analyzer 10 system.

The system, used in conjunction with the ChLIA products, functions as a compact automation solution in small- to medium-sized laboratories, or complements high-throughput-devices in large-sized laboratories. Test- and lot-specific information, including stored standard curves, are imported into the database by means of an RFID code, enabling error-free and convenient loading, along with efficient and secure test evaluation.  

The EUROIMMUN RA Analyzer 10 allows continuous loading—also as part of a testing line—to ensure every sample is processed with minimal effort and shorter reaction times as a single determination. The ChLIA technology further minimizes reaction times, with total analysis in 30 minutes or less. In addition, the preferred processing of emergency (STAT) samples gives laboratories with different requirements and sample volumes unparalleled flexibility in their laboratory routine.

Lyme disease represents the most frequent tick-borne infection in the northern hemisphere, while EBV remains one of the most common human pathogens (herpesvirus 4) with a prevalence of up to 99%. Without treatment, Borrelia infections can lead to severe clinical symptoms. In case of EBV it is important to ensure early diagnosis due its high contagiousness. By introducing assays for the RA Analyzer 10, we’ve extended our already comprehensive portfolio of serological assays for Lyme disease and EBV diagnostics.”

Wolfgang Schlumberger, Ph.D., CEO of EUROIMMUN, a PerkinElmer company

EUROIMMUN is widely recognized as a global leader in autoimmune testing and an emerging force in infectious disease, allergy and molecular genetic testing. Its expertise and capabilities extend across immunology, cell biology, histology, biochemistry and molecular biology.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Revvity. (2023, August 23). PerkinElmer unveils CE-marked infectious disease immunoassays on EUROIMMUN random access instrument. News-Medical. Retrieved on November 23, 2024 from https://www.news-medical.net/news/20190711/PerkinElmer-unveils-CE-marked-infectious-disease-immunoassays-on-EUROIMMUN-random-access-instrument.aspx.

  • MLA

    Revvity. "PerkinElmer unveils CE-marked infectious disease immunoassays on EUROIMMUN random access instrument". News-Medical. 23 November 2024. <https://www.news-medical.net/news/20190711/PerkinElmer-unveils-CE-marked-infectious-disease-immunoassays-on-EUROIMMUN-random-access-instrument.aspx>.

  • Chicago

    Revvity. "PerkinElmer unveils CE-marked infectious disease immunoassays on EUROIMMUN random access instrument". News-Medical. https://www.news-medical.net/news/20190711/PerkinElmer-unveils-CE-marked-infectious-disease-immunoassays-on-EUROIMMUN-random-access-instrument.aspx. (accessed November 23, 2024).

  • Harvard

    Revvity. 2023. PerkinElmer unveils CE-marked infectious disease immunoassays on EUROIMMUN random access instrument. News-Medical, viewed 23 November 2024, https://www.news-medical.net/news/20190711/PerkinElmer-unveils-CE-marked-infectious-disease-immunoassays-on-EUROIMMUN-random-access-instrument.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.